Kamelia Behnia
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Diabetes, Cardiovascular Risks, and Lipoproteins, Neurotransmitter Receptor Influence on Behavior, Synthesis and biological activity, Cannabis and Cannabinoid Research, Diabetes Management and Research
Most-Cited Works
- → Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays(2004)1,285 cited
- → Design of amidobenzimidazole STING receptor agonists with systemic activity(2018)823 cited
- → 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N -(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan -Src Kinase Inhibitor(2006)395 cited
- → Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils(2016)158 cited
- → Oxygen Consumption Characteristics of Porcine Hepatocytes(1999)131 cited
- → Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors